Please assess the completion status of the following clinical trial:

Trial Title: Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with histologically/cystologically confirmed advanced cancers including solid tumors, multiple myeloma, and lymphoma~* Radiographic evidence of at least one bone metastasis (or lytic bone lesion from multiple myeloma); ECOG performance status 0, 1, or 2~* Adequate organ function~Exclusion Criteria:~* Diagnosis of breast or prostate cancer~* Current or prior intravenous bisphosphonate administration~* Current or prior oral bisphosphonates for bone metastases, life expectancy of less than 6 months~* Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- zoledronic acid (Type: ACTIVE_COMPARATOR): denosumab placebo with active zoledronic acid
- denosumab (Type: EXPERIMENTAL): active denosumab with zoledronic acid placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).